European Neuroendocrine Tumour Society
ENETS is a registered society that was set up to develop the highest standards of care for the management of Neuroendocrine Tumours. Due to their relatively rare occurrence, research and patient care guidelines, previously had been lacking and ENETS focuses on these issues.
The founding members sought to unify neuroendocrine tumor disease research amongst European medical professionals. The primary aim was to integrate basic and clinical research with teaching and to establish guidelines for the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP NETs). In 2004 and 2005, the “Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours” were developed and, in April 2005, were published in the journal ‘Neuroendocrinology’. Revised Guidelines followed in 2006, 2007 and 2011 along with TNM classifications. The Guidelines continue to be updated regularly.
ENETS has gradually attracted members from throughout Europe, and has expanded to include members from, Russia, Australia, South America, Canada, China and India, and the U.S. A. At the same time, the Society has formed valuable relationships within the pharmaceutical industry, namely with Novartis Pharma AG in Basel, Switzerland, and IPSEN Biotech in Paris and also Pfizer. ENETS cooperates with the German Neuroendocrine Tumor Network (NET-WORKs), UKI-NETs, and similar organizations in most member countries.
ENETS is steered by an executive committee composed of nine members. Professor Martyn Caplin is the current Chairman of ENETS and is based at the Royal Free Hospital in Hampstead where he continues to develop both clinical management and scientific research into NETs.
Ref: ENETS organisation information sourced from www.enets.org